THE OFFERING
Shares of common stock offered 1,400,000 shares of our common stock (based on assumed public offering price of $5.00 per share).
Assumed public offering price $5.00 per share
Common stock outstanding before the offering 2,881,104 shares.(1)
Common stock outstanding after the offering 4,281,104 shares (or 4,491,104 shares if the underwriter exercises its overallotment option in full) at an assumed offering price of $5.00 per share, the midpoint of the offering range.
Use of proceeds We expect to receive approximately $6,160,000 in net proceeds from the sale of our shares of common stock offered by us in this offering (approximately $7,136,500 if the underwriter exercises its over-allotment option in full), after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds received from this offering for general corporate purposes, which may include funding working capital, capital expenditures, research and development, sales and marketing activities, and the repayment of indebtedness. See “Use of Proceeds” on page 16 for a more complete description of the intended use of proceeds from this offering.
Listing Currently, our common stock is traded on the OTCQB under the symbol “HLYK.” We have applied to list our common stock for trading on Nasdaq under the symbol “HLYK”. To meet the Nasdaq minimum listing requirements, we may be required to have our related party debtholder, Dr. Michael Dent, convert a portion or all of the convertible debt outstanding to him. If our shares of common stock are not approved for listing on Nasdaq, we will not consummate this offering. No assurance can be given that we will meet the minimum listing requirements or that our application will be approved.
Lock-up Agreements We have agreed with the underwriter not to sell additional equity securities for a period of 180 days after the closing date of this offering, subject to certain exceptions. Our directors, officers and holders of 5% or more of our common stock have agreed with the underwriter not to offer for sale, sell, contract to sell, pledge or otherwise dispose of any of their shares of our common stock or securities convertible into our common stock, subject to certain exceptions, for a period of 180 days after the closing date of this offering. See “Underwriting”.
Risk Factors Investing in our securities is highly speculative and involves a significant degree of risk. You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the “Risk Factors” section beginning on page 5 of this prospectus before deciding whether or not to invest in our common stock.
(1) Represents the number of shares of our common stock outstanding as of February 6, 2026. Excludes (i) 135,646 shares of common stock issuable upon exercise of outstanding options with a weighted average exercise price of $4.26, (ii) 694,158 shares of common stock issuable upon exercise of outstanding warrants with a weighted average exercise price of $13.30, (iii) 275,311 unissued shares subject to future vesting requirements granted pursuant to our Employee Incentive Plans, (iv) 1,401,102 shares issuable upon the conversion of notes payable to related parties, (v) 22,052 common earned but unissued shares pursuant to consulting agreements, and (vi) up to 137,500 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock.
AI
Market Data 
Markets 
